Avacta Group Plc (AIM:AVCT)
London · Delayed Price · Currency is GBP · Price in GBX 47.00
-4.50 (-8.74%)
Aug 1, 2025, 4:35 PM GMT+1
Avacta Group Company Description
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally.
Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities.
The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors.
The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Avacta Group Plc
| Country | United Kingdom |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 151 |
| CEO | Christina Coughlin |
Contact Details
Address: Scale Space White City Imperial College Campus London, W12 7RZ United Kingdom | |
| Phone | 44 203 9110353 |
| Website | avacta.com |
Stock Details
| Ticker Symbol | AVCT |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BYYW9G87 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Christina Coughlin | Chief Executive Officer |
| Brian Hahn | Chief Financial Officer |
| Karen Harrison | Chief Operating Officer |